Pelthos Therapeutics (NYSEAM:PTHS) FY Conference Transcript

Summary of Pelthos Therapeutics FY Conference Call Company Overview - Company: Pelthos Therapeutics (NYSEAM:PTHS) - Lead Product: Zelzuvmi (Berdazimer), a topical agent for treating molluscum contagiosum and external genital warts - Acquisition: Recently acquired Xepi (Ozenoxacin), a topical treatment for impetigo Key Points Payer Win and Market Access - Pelthos secured a major payer win covering approximately 20 million lives, effective December 1, 2025, which significantly improves access for patients [2][3] - Prior to this win, only 5% of prescriptions were processed through this plan, despite covering 20% of the lives [2] - Currently, 30% of Pelthos's business is Medicaid, with 70% of lives covered without formal contracts [4] Product Development and Rights - Pelthos retains worldwide rights to Zelzuvmi and the right to develop it for external genital warts, while Ligand holds the intellectual property for other indications [6][7] - The company operates the API manufacturing for the NitroSil platform, which could serve as a revenue source if partnered with other companies [10] Clinical Efficacy and Market Need - Molluscum contagiosum has a high prevalence, with about 6 million new cases annually, predominantly in children [15] - Zelzuvmi is the first FDA-approved at-home treatment, addressing a significant unmet need as 73% of patients under 10 are untreated [16] - Clinical trials showed over 30% of patients achieved complete clearance, with 77% of parents reporting a clinically meaningful impact even without complete clearance [20] Competitive Landscape - The market currently has two main products: Zelzuvmi and YCANTH, with different treatment modalities [21] - Pelthos aims to position Zelzuvmi as the first-line therapy, while acknowledging that both products can coexist in the market [24] Commercial Strategy - Pelthos launched with 50 sales representatives, targeting 8,000 healthcare providers, and plans to expand to 64 reps to cover all major metropolitan areas [28] - As of October, Pelthos had approximately 2,200 unique prescribers, with a 41% increase in prescriptions from September to October [36] Financial Metrics - The gross-to-net revenue for Q3 was 25.3%, with expectations to rise to the high 20s for Q4 and stabilize in the mid- to high 30s for 2026 [39] - The company has a strategy to minimize out-of-pocket costs for patients, aiming for zero out-of-pocket payments for commercially insured patients [43] Acquisition of Xepi - Xepi was acquired due to its potential in treating impetigo, with about 3 million cases annually, primarily in children [46] - The acquisition allows Pelthos to leverage its existing commercial infrastructure and target the same audience as Zelzuvmi [47] - Xepi's exclusivity runs until early 2032, while Zelzuvmi's exclusivity extends to 2035, with a potential extension to mid-2037 [52] Manufacturing and Barriers to Entry - Pelthos believes its specialized manufacturing capabilities create a barrier to entry for competitors, as the production process for its products is complex [53] Conclusion Pelthos Therapeutics is strategically positioned in the dermatological market with its innovative products, strong payer relationships, and a clear plan for growth through both organic expansion and acquisitions. The company is focused on addressing significant unmet needs in pediatric dermatology while maintaining a competitive edge through its unique manufacturing processes and product offerings.